plerixafor has been researched along with Alzheimer Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garino, C; Kraus, JL; Laras, Y; Mallet, B; Moret, V; Norreel, JC; Pietrancosta, N; Quéléver, G; Rolland, A | 1 |
| Barbiro, B; Ezra, A; Gavriel, Y; Rabinovich-Nikitin, I; Solomon, B | 1 |
| Bae, JS; Jin, HK; Lee, JE; Lee, JK; Min, WK; Schuchman, EH; Shin, JW | 1 |
| Cotman, CW; Parachikova, A | 1 |
4 other study(ies) available for plerixafor and Alzheimer Disease
| Article | Year |
|---|---|
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
Topics: Alzheimer Disease; Animals; Chelating Agents; Clioquinol; Copper; Heterocyclic Compounds, 1-Ring; Molecular Structure; Rats; Structure-Activity Relationship | 2006 |
Subcutaneous Administration of AMD3100 into Mice Models of Alzheimer's Disease Ameliorated Cognitive Impairment, Reduced Neuroinflammation, and Improved Pathophysiological Markers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-HIV Agents; Benzylamines; Biomarkers; Cognitive Dysfunction; Cyclams; Disease Models, Animal; Inflammation; Inflammation Mediators; Injections, Intraventricular; Injections, Subcutaneous; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peptide Fragments | 2020 |
Combined effects of hematopoietic progenitor cell mobilization from bone marrow by granulocyte colony stimulating factor and AMD3100 and chemotaxis into the brain using stromal cell-derived factor-1α in an Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Animals; Benzylamines; Bone Marrow Cells; Brain; Chemokine CXCL12; Chemotaxis; Cyclams; Disease Models, Animal; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Mice; Mice, Inbred C57BL; Mice, Transgenic | 2011 |
Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzylamines; Biomarkers; Brain; Chemokine CXCL12; Cyclams; Disease Models, Animal; Down-Regulation; Encephalitis; Gene Expression Regulation; Heterocyclic Compounds; Hippocampus; Humans; Learning Disabilities; Mice; Mice, Inbred C57BL; Mice, Transgenic; Plaque, Amyloid; Receptors, CXCR4; RNA, Messenger; Synaptic Transmission | 2007 |